SCHEMBL5135967

SCHEMBL5135967

CCCCn1c(CN(Cc2cc(C)ccc2C)Cc2cccc3ccccc23)cnc1-c1ccccc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.38
CYP2C19 P33261 2/20 0.37
TP53 P04637 1/20 0.36
PGR P06401 1/20 0.35
RORA P35398 1/20 0.35
RORC P51449 1/20 0.35
RORB Q92753 1/20 0.35
CNR2 P34972 2/20 0.35
C5AR1 P21730 1/20 0.35
ALDH1A1 P00352 1/20 0.34
LMNA P02545 1/20 0.34
HPGD P15428 1/20 0.34
HTT P42858 1/20 0.34
ESR1 P03372 1/20 0.34
ESR2 Q92731 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
ICMT O60725 2/20 0.33
NR1H3 Q13133 1/20 0.33
CYP1A2 P05177 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5135653 0.94 TSHR (0.37) TSHRCYP2C19TP53PGRRORA
SCHEMBL5135274 0.92 TSHR (0.41) TSHRCYP2C19CNR2C5AR1ALDH1A1
SCHEMBL5136057 0.91 TSHR (0.37) TSHRCYP2C19CNR2C5AR1ALDH1A1
SCHEMBL5135729 0.90 PPARG (0.40) TSHRCYP2C19TP53CNR2C5AR1
SCHEMBL5072207 0.90 PPARG (0.39) TSHRCYP2C19CNR2C5AR1LMNA
SCHEMBL5137856 0.89 C5AR1 (0.39) TSHRCYP2C19CNR2C5AR1ALDH1A1
SCHEMBL5072389 0.89 TSHR (0.41) TSHRCYP2C19CNR2C5AR1ALDH1A1
SCHEMBL5137588 0.88 TSHR (0.41) TSHRTP53PGRRORARORC
SCHEMBL5136123 0.87 C5AR1 (0.38) TSHRCYP2C19CNR2C5AR1ALDH1A1
SCHEMBL5136502 0.87 C5AR1 (0.38) TSHRCYP2C19C5AR1ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed